Choosing Wisely: Insights from an MAIC and eXalt3

EP: 1.The Evolution of ALK+ NSCLC Care

EP: 2.Lorlatinib in Focus: Survival, Brain Metastases, and Beyond

Now Viewing

EP: 3.Choosing Wisely: Insights from an MAIC and eXalt3

EP: 4.Applying Trial Data to Real-World Practice in ALK+ NSCLC

EP: 5.Key Differences Among ALK Inhibitors

EP: 6.Navigating ALK Inhibitor Toxicities

EP: 7.Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs

EP: 8.Long-Term Success: Educating and Supporting Patients on ALK Inhibitors

EP: 9.Equitable Access to Molecular Testing and Treatment Prioritization

EP: 10.Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC

EP: 11.Education and Support After Progression ALK Inhibitors

EP: 12.Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy

Comparative Data Analysis and Ensartinib Approval

Key Themes:

• Matching-adjusted indirect comparisons (MAIC) of lorlatinib versus alectinib or brigatinib
• Overview of the eXalt3 study for ensartinib
• Implications of ensartinib’s December 2024 FDA approval

Notable Insights:

• Dr Dietrich analyzed insights from the MAIC of lorlatinib versus other ALK inhibitors

Dr Lovly provided an overview of the eXalt3 study following ensartinib’s recent FDA approval in December 2024